Anti-Fibrinolytic Drugs - Argentina

Argentina

Argentina is expected to witness a significant growth in revenue within the Anti-Fibrinolytic Drugs market.
By 2024, the projected revenue is set to reach a substantial amount of €58.06m.
This growth is expected to continue with an annual growth rate (CAGR 2024-2029) of 4.15%, resulting in a market volume of €71.14m by 2029.
In comparison to other countries, United States is predicted to generate the highest revenue, with an impressive amount of €9,047.00m in 2024.
However, Argentina's growth potential within the market presents a promising outlook for the country's healthcare sector.
Argentina's market for anti-fibrinolytic drugs is experiencing steady growth due to increasing awareness and demand for these medications.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Argentina has been steadily growing over the past few years.

Customer preferences: One of the main factors driving this growth is the increasing prevalence of bleeding disorders in the country. As a result, there is a growing demand for drugs that can help control bleeding and prevent excessive blood loss. Additionally, there is a growing awareness among healthcare professionals and patients about the benefits of anti-fibrinolytic drugs, which has also contributed to the growth of the market.

Trends in the market: Another trend in the market is the increasing use of anti-fibrinolytic drugs in surgical procedures. With the growing number of surgeries being performed in the country, there is a higher demand for drugs that can help control bleeding during and after surgery. This has led to an increase in the use of anti-fibrinolytic drugs in hospitals and clinics across the country.

Local special circumstances: One of the unique factors in the Anti-Fibrinolytic Drugs market in Argentina is the presence of a large number of local manufacturers. These manufacturers have been able to compete with international players by offering lower-priced alternatives to the more expensive imported drugs. This has helped to keep prices in the market relatively low, which has made anti-fibrinolytic drugs more accessible to a wider range of patients.

Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in Argentina is also being driven by underlying macroeconomic factors. The country has been experiencing steady economic growth over the past few years, which has led to an increase in healthcare spending. Additionally, the government has been investing in healthcare infrastructure and services, which has helped to improve access to healthcare for patients across the country. These factors have created a favorable environment for the growth of the Anti-Fibrinolytic Drugs market in Argentina.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.